上海復旦張江生物醫藥股份有限公司

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code:1349)

INDICATIVE ANNOUNCEMENT
FZ-AD005 ANTIBODY DRUG CONJUGATE FOR INJECTION FOR THE TREATMENT OF ADVANCED SOLID TUMORS RECEIVED THE ACCEPTANCE NOTICE FOR THE INVESTIGATIONAL NEW DRUG APPLICATION

This announcement is made by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.* (the "**Company**") on a voluntary basis.

The board of directors (the "**Board**") of the Company is pleased to announce that, the Company has received the Acceptance Notice (《受理通知書》) issued by the National Medical Products Administration of the PRC (the "**NMPA**"). The investigational new drug (the "**IND**") application for Phase I clinical trial of FZ-AD005 antibody drug conjugate for injection (DLL3-BB05 ADC, the "**Drug**") for the treatment of advanced solid tumors has been accepted. Relevant information is as follows:

ABOUT THE DRUG

Drug name:	FZ-AD005 antibody drug conjugate for injection
Registration type:	Class 1 therapeutic biological products
Application matter:	Registration of Clinical Trial of Domestic Production of Pharmaceutical Product
Acceptance No.	CXSL2300717
Applicant:	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd
Review conclusion:	Accepted upon review according to the requirements of Article 32 of the Administrative License Law of the People's Republic of China.

In recent years, the Company has built a new Linker-Drug platform ("**BB05 Platform**") with independent intellectual property rights in respect of small molecule. The Drug is the third new generation antitumor antibody-drug conjugate (ADC) drug on the BB05 Platform. It is generated by a recombinant anti-DLL3 human mouse chimeric antibody ("**DLL3**") coupled with BB05. According to the public data, the Drug is currently first topoisomerase inhibitors ADC targeting DLL3. The Drug can bind to DLL3-positive tumor cells and endocytosis, releasing small molecule cytotoxic drugs (topoisomerase I inhibitors) in lysosomes by protease cleavage to kill the tumor cells. The Drug is intended to be developed for the treatment of advanced solid tumors including but not limited to small cell lung cancer, large cell neuroendocrine carcinoma and prostatic cancer, etc.

Due to the high-tech, high-risk and high-value-added characteristics of pharmaceutical products, and the long cycle and numerous stages in the process, there are uncertainties in drug pre-clinical research, clinical trial and commercialization. These many stages make it susceptible to uncertainties and therefore, investors are advised to make cautious decisions and pay careful attention to investment risks. The Company will actively facilitate the above research and development project and fulfill its information disclosure obligations in a timely manner for subsequent progress in strict accordance with relevant regulations.

By order of the Board
Zhao Da Jun
Chairman

As at the date on the publication of this announcement, the Board comprises:

Mr. Zhao Da Jun (Executive Director)
Ms. Xue Yan (Executive Director)
Mr. Shen Bo (Non-executive Director)
Ms. Yu Xiao Yang (Non-executive Director)
Mr. Wang Hong Guang (Independent Non-executive Director)
Mr. Lam Siu Wing (Independent Non-executive Director)
Mr. Xu Pei Long (Independent Non-executive Director)

Shanghai, the PRC

20 October 2023
* *For identification purpose only*